Lege Artis Medicinae

[Incretin based therapies from a clinician’s view]

KIS János Tibor1

SEPTEMBER 20, 2010

Lege Artis Medicinae - 2010;20(09)

[The incretin based therapies give new and promising opportunities in the care of type 2 diabetic patients. Right now two kinds of incretinmimetics and three incretinenhancers are available in Hungary. There are more and more agents and more industrial products. There are several publications about the advantages of these products, but only a few data can be found about the comparison of them. The author tries to evaluate the incretin based therapies, and tries to help the clinicians choose the right one.]

AFFILIATIONS

  1. Budai Irgalmasrendi Kórház, Belgyógyászati Osztály

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[The Identity of Psychiatrists – a Criticism of Psychiatry by Thomas Szasz]

KELEMEN Gábor

Lege Artis Medicinae

[The multidisciplinary pathological examination of colorectal carcinomas - From the biopsy sample to the K-RAS mutation analysis]

BOGNER Barna

[BACKGROUND - The role of pathologist in the reporting of colorectal carcinomas (CRC) has dramatically changed in the past 20 years. This change has been generated by the enormous progress in the surgical, radiological, oncological and pathological techniques and their interactions. AIM - To interpret the role of pathologist in the colorectal multidisciplinary team. METHODS - The most important histopathological prognostic and predictive factors, the surgical planes, the involvement of circumferencial margin, the regression grade after neoadjuvant chemoradiotherapy were assessed in 964 patients treated with operable colorectal cancer during 2001-2007 in the County Hospital of Baranya and the four nearby city hospitals. RESULTS - Most of our patients (>75%) were treated with advanced stage tumors. The lymph nodes were harvested through careful slicing, visual inspection and palpation - accordingly the average lymph node count increased from 7.45 to 19.0. After using elastic fibre stain we detected twice as much vascular invasion then before. The results of the surgical quality after TME and APER were somewhat dissapointing. Although the ratio of the specimens resected in the mesoretal fascial plane was comparable to the international results (39.8%), the ratio of resections in the muscularis propria plane was unacceptably high (47.8%) and it was more pronounced (50-100%) between the low volume surgeons of the small city hospitals. The involvement of the circumferencial resection margin was affected by the advanced pT and pN stage, the vascular invasion, the surgical plane, the type and number of resection performed by the surgeons, the regression grade after preoperative chemoradiotherapy and the gender. CONCLUSIONS - In addition to the traditional histopathological features the pathologist has to investigate the quality features of the preopreative assessment, the surgical planes of excision and the grade of regression after neoadjuvant chemoradiation and feed back these results to the members of the CRC multidisciplinary team. The optimal treatment of the CRC can be achived only in this setting.]

Lege Artis Medicinae

[Reform of the Hungarian health care - Where are we now?]

LANTOS Zoltán

Lege Artis Medicinae

[Dabigatran treatment prevents stroke in non-valvular atrial fibrillation]

NAGY Viktor

Lege Artis Medicinae

[Efficacy and safety of sitagliptin during long term treatment in patients with type 2 diabetes]

HIDVÉGI Tibor

[Due to the progressive nature of the type 2 diabetes mellitus and treatment requires prolonged lifestyle and/or pharmacologic management, the long term efficacy, durability and safety of newer antihyperglycemic agents are important considerations. Metformin is the most common prescribed oral antihyperglycemic agent (OHA) for initial therapy. Often, initial single oral agent is not sufficient to maintain good glucose control, combination of OHA are usually required to manage patients with type 2 diabetes. Incretinbased therapies (e.g. dipeptidyl peptidase 4 (DPP 4) inhibitors and analogues of glucagon like peptide 1) are newer compounds available for the treatment of type 2 diabetes. Sitagliptin is a once-daily OHA with a novel mechanism of action that targets the incretin axis. Addition of sitagliptin to ongoing metformin therapy was well tolerated and resulted in significant glycemic improvement after 30-104 weeks of treatment in patients with type 2 diabetes.]

All articles in the issue

Related contents

Lege Artis Medicinae

[INCRETIN MIMETICS AND INCRETIN ENHANCERS: NEW THERAPEUTIC TOOLS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS]

JERMENDY György

[Incretins are hormone-like peptides secreted by specific cells of the small intestine mucosa. Their two main representatives are the glucagon-likepeptide- 1 (GLP-1 and the glucose-dependent insulinotropic peptide, (GIP) the release of which is stimulated by meals. The main action of incretins is to enhance insulin secretion following meals. They are rapidly metabolized in the circulation by the enzyme dipeptidyl peptidase IV (DPP-IV). Patients with type 2 diabetes have markedly impaired incretin-mediated insulin secretion mainly due to decreased secretion of GLP-1. Research in the last years has opened up a new therapeutic option to treat patients with type 2 diabetes. Continuous intravenous use of GLP-1 cannot be widely used in clinical practice; however, GLP-1-mimetics that have an agonist effect on the receptors but are resistant to degradation by DPP-IV have been developed. The GLP-1 agonist xenatide, due to its incretin mimetic property, stimulates postprandial insulin secretion, suppresses glucagon secretion, delays gastric emptying and increases sense of fullness thus resulting in weight reduction. In experimental settings, exenatide has a documented beta-cell protecting property. Its disadvantages include the fact that it can only be administered subcutaneously and that it has a well characterized side effect profile. On the contrary, the DPP-IV inhibiting incretin enhancers (sitagliptin, vildagliptin) can be used orally and are well tolerated. Exenatide, sitagliptin and vildagliptin are the first representatives of incretin mimetics and incretin enhancers. Sitagliptin has been available in Hungary since August, 2008. Their effect to reduce blood glucose and HbA1c should mainly be exploited in combination therapy, preferably with metformin. The availability of incretin mimetics and incretin enhancers will offer new therapeutic options for treating patients with type 2 diabetes. Nevertheless, the final assessment of these new drugs will require long-term experience in the clinical practice.]

Lege Artis Medicinae

[The role of the DPP-4 inhibitor sitagliptin in the therapy of type 2 diabetes, in light of the new guidelines]

HIDVÉGI Tibor

[Type 2 diabetes has become a global public health problem, threatening the economies of all nations, as a consequence of rapid urbanisation, changing eating habits, sedentary lifestyle and obesity. Asian populations tend to develop diabetes at younger ages and lower body mass index compared with Caucasians. The latest guidelines of the American Diabetes Association and the European Association for the Study of Diabetes recommend lifestyle interventions as the first step for patients with newly diagnosed type 2 diabetes. The widely used metformin remains one of the first-line drugs for type 2 diabetes. If monotherapy alone does not achieve or maintain the target HbA1c level, addition of a second oral agent is recommended as a second step. The highly selective dipetidyl peptidase-4 inhibitor sitagliptin and metformin are efficient and well tolerable. The complementary effects of sitagliptin and metformin lead to an efficient, safe and long-term improvement in glycaemic control.]

Lege Artis Medicinae

[Rationality of incretin based therapy in type 1 diabetes]

KIS János Tibor, GROSZ Andrea, SCHANDL László

[The incretin based therapy is applied at the early stage of type 2 diabetes mellitus. The mechanism of these drugs is partly independent from the functional β cells, therefore therapeutic effect can be expected at the late stage of type 2 diabetes mellitus, what is more in the case of type 1 diabetes. The type 1 diabetes mellitus can be used as a model to test these non-insulin secretion effects. In our work we summarize those clinical trials, in which incretin based therapy was used as a treatment of type 1 diabetic patients.]

LAM Extra for General Practicioners

[The possibilities of pharmacological treatment of obesity]

PADOS Gyula, SIMONYI Gábor, BEDROS J. Róbert

[There have been attempts to treat obesity with medicines for nearly 100 years, since the discovery of ephedrine. For decades amphetamine derivates and agents stimulating or inhibiting the release of noradrenaline and dopamine have been applied. However, most of theses drugs had to be gradually withdrawn, due to their adverse effects on the cardiovascular and central nervous system or their sympaticotonic effect. Dexfenfluramine (Isolipan), which was introduced in the 90s, did not have such side effects, but it turned out to potentially cause valvular heart disease. Finally, sibutramin (Reductil) was introduced, which again had to be withdrawn in 2010 due to its hypertensive and cardiovascular side effects. After all, we were left without any appetite-suppressant drugs. Orlistat therapy, (Xenical 120 mg, alli 60 mg - OTC), which inhibits the absorption of fat, can eliminate only 30% of the consumed food's fat content, at the price of gastrointestinal side effects. The latest result of research carried out wordwide is that in 2012 the FDA approved commercial distribution of the selective 5HT2/c serotonin agonist lorcaserin (Belviq), which enhances satiety, in the USA. Unfortunately, in 2013 the EMEA temporarily postponed the lauch of this drug, until certain adverse effects are excluded. For diabetic patients, the GLP-1 agonist exenatid and the GLP-analog liraglutid, which can also reduce body weight, are available in the form of injections. ]

Lege Artis Medicinae

[Efficacy and safety of sitagliptin during long term treatment in patients with type 2 diabetes]

HIDVÉGI Tibor

[Due to the progressive nature of the type 2 diabetes mellitus and treatment requires prolonged lifestyle and/or pharmacologic management, the long term efficacy, durability and safety of newer antihyperglycemic agents are important considerations. Metformin is the most common prescribed oral antihyperglycemic agent (OHA) for initial therapy. Often, initial single oral agent is not sufficient to maintain good glucose control, combination of OHA are usually required to manage patients with type 2 diabetes. Incretinbased therapies (e.g. dipeptidyl peptidase 4 (DPP 4) inhibitors and analogues of glucagon like peptide 1) are newer compounds available for the treatment of type 2 diabetes. Sitagliptin is a once-daily OHA with a novel mechanism of action that targets the incretin axis. Addition of sitagliptin to ongoing metformin therapy was well tolerated and resulted in significant glycemic improvement after 30-104 weeks of treatment in patients with type 2 diabetes.]